CC
ALIM

Clearline Capital’s Alimera Sciences ALIM Stock Holding History

Clearline Capital’s Portfolio ALIM Stock Details ALIM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,085,291
Closed -$8.13M – 160
2024
Q1 		$8.13M Sell
2,085,291
-83,852
-4% -$319K 0.4% 35
2023
Q4 		$9.37M Sell
2,169,143
-166,150
-7% -$561K 0.57% 32
2023
Q3 		$7.24M Buy
+2,335,293
New +$7.72M 0.62% 42

Other funds holding ALIM

CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Clearline Capital's ALIM Position: Q2 2024 in Review

Clearline Capital sold out of Alimera Sciences (ALIM) in Q2 2024, closing a stake of 2,085,291 shares — an estimated $8.13M sold.

Clearline Capital first reported a position in ALIM in Q3 2023 and held it in 3 quarters. The position peaked at $9.37M in Q4 2023. 52 funds tracked by Wall St. Rank hold ALIM as of Q2 2024.

  • Clearline Capital reported no remaining Alimera Sciences position as of Q2 2024 after selling out during the quarter.
  • Clearline Capital sold 2,085,291 Alimera Sciences shares in Q2 2024, an estimated $8.13M.
  • Clearline Capital first reported a position in Alimera Sciences in Q3 2023 and held it in 3 quarters.
  • Clearline Capital's Alimera Sciences position peaked at $9.37M in Q4 2023.
  • 52 funds tracked by Wall St. Rank held Alimera Sciences as of Q2 2024.

Based on Clearline Capital's 13F filing for Q2 2024, filed 15 Aug 2024.